HUE046617T2 - Pirazol-aminopirimidin-származékok mint LRRK2 modulátorok - Google Patents

Pirazol-aminopirimidin-származékok mint LRRK2 modulátorok

Info

Publication number
HUE046617T2
HUE046617T2 HUE16180927A HUE16180927A HUE046617T2 HU E046617 T2 HUE046617 T2 HU E046617T2 HU E16180927 A HUE16180927 A HU E16180927A HU E16180927 A HUE16180927 A HU E16180927A HU E046617 T2 HUE046617 T2 HU E046617T2
Authority
HU
Hungary
Prior art keywords
aminopyrimidine derivatives
pyrazole
lrrk2 modulators
lrrk2
modulators
Prior art date
Application number
HUE16180927A
Other languages
English (en)
Inventor
Charles Baker-Glenn
Daniel Jon Burdick
Mark Chambers
Huifen Chen
Anthony Estrada
Zachary Kevin Sweeney
Bryan K Chan
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of HUE046617T2 publication Critical patent/HUE046617T2/hu

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HUE16180927A 2010-11-10 2011-11-09 Pirazol-aminopirimidin-származékok mint LRRK2 modulátorok HUE046617T2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41227310P 2010-11-10 2010-11-10
US201161546613P 2011-10-13 2011-10-13

Publications (1)

Publication Number Publication Date
HUE046617T2 true HUE046617T2 (hu) 2020-03-30

Family

ID=44983512

Family Applications (2)

Application Number Title Priority Date Filing Date
HUE11782588A HUE037844T2 (hu) 2010-11-10 2011-11-09 Pirazol-aminopirimidin-származékok mint LRRK2 modulátorok
HUE16180927A HUE046617T2 (hu) 2010-11-10 2011-11-09 Pirazol-aminopirimidin-származékok mint LRRK2 modulátorok

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HUE11782588A HUE037844T2 (hu) 2010-11-10 2011-11-09 Pirazol-aminopirimidin-származékok mint LRRK2 modulátorok

Country Status (28)

Country Link
US (1) US8815882B2 (hu)
EP (3) EP3590933B1 (hu)
JP (3) JP5986094B2 (hu)
KR (1) KR101566091B1 (hu)
CN (1) CN103313978B (hu)
AR (1) AR083813A1 (hu)
AU (1) AU2011328139A1 (hu)
BR (1) BR112013011600B1 (hu)
CA (2) CA2812669C (hu)
CY (1) CY1120073T1 (hu)
DK (2) DK3124483T3 (hu)
EC (1) ECSP13012611A (hu)
ES (2) ES2746134T3 (hu)
HK (1) HK1187605A1 (hu)
HR (2) HRP20172006T1 (hu)
HU (2) HUE037844T2 (hu)
IL (1) IL225234A0 (hu)
LT (2) LT3124483T (hu)
MA (1) MA34644B1 (hu)
MX (1) MX2013005199A (hu)
NO (1) NO2638031T3 (hu)
PL (2) PL2638031T3 (hu)
PT (2) PT2638031T (hu)
RS (2) RS56583B1 (hu)
SG (1) SG189043A1 (hu)
SI (2) SI3124483T1 (hu)
TW (1) TW201302733A (hu)
WO (1) WO2012062783A1 (hu)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140041583A (ko) 2011-05-23 2014-04-04 엘란 파마슈티컬스, 엘엘씨 Lrrk2 키나제 활성의 억제제
BR112014011219B1 (pt) * 2011-11-29 2022-08-23 Genentech, Inc. Derivados de aminopirimidina, seus usos, e composição farmacêutica
AR089182A1 (es) 2011-11-29 2014-08-06 Hoffmann La Roche Derivados de aminopirimidina como moduladores de lrrk2
BR112014011850B1 (pt) 2011-11-29 2022-01-11 Genentech, Inc Derivados de aminopirimidina, seus usos, e composição farmacêutica
US20140228384A1 (en) * 2011-11-29 2014-08-14 Genentech, Inc. Assays and biomarkers for lrrk2
PT2785711T (pt) * 2011-11-29 2016-09-30 Hoffmann La Roche Derivados de 2-(fenil ou pirid-3- il)aminopiridinacomo moduladores de lrrk2 quinase, para o tratamento da doença de parkinson
KR101996699B1 (ko) 2011-11-30 2019-07-04 제넨테크, 인크. Lrrk2에 대해 양전자 방사 단층촬영(pet) 이미징을 위한 불소-18 및 탄소-11 표지된 방사선 리간드
MX363118B (es) * 2012-05-03 2019-03-11 Genentech Inc Derivados de pirazol aminopirimidina como moduladores de cinasa 2 de repeticion rica en leucina (lrrk2).
EP2844658B1 (en) * 2012-05-03 2019-03-20 Genentech, Inc. Pyrazole aminopyrimidine derivatives as lrrk2 modulators for use in the treatment of parkinson's disease
JP6189948B2 (ja) 2012-06-29 2017-08-30 ファイザー・インク LRRK2阻害薬としての新規な4−(置換アミノ)−7H−ピロロ[2,3−d]ピリミジン
WO2014060381A1 (de) 2012-10-18 2014-04-24 Bayer Cropscience Ag Heterocyclische verbindungen als schädlingsbekämpfungsmittel
WO2014134772A1 (en) * 2013-03-04 2014-09-12 Merck Sharp & Dohme Corp. Compounds inhibiting leucine-rich repeat kinase enzyme activity
CN105814037B (zh) 2013-12-17 2018-11-30 默克专利股份公司 作为丙酮酸脱氢酶激酶的抑制剂的n1-(3,3,3-三氟-2-羟基-2-甲基丙酰基)-哌啶衍生物
US9695171B2 (en) 2013-12-17 2017-07-04 Pfizer Inc. 3,4-disubstituted-1 H-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7H-pyrrolo[2,3-c]pyridazines as LRRK2 inhibitors
ES2812605T3 (es) 2013-12-20 2021-03-17 Signal Pharm Llc Compuestos de diaminopirimidilo sustituidos, composiciones de los mismos y procedimientos de tratamiento con ellos
SG11201605342UA (en) 2014-01-29 2016-08-30 Glaxosmithkline Ip Dev Ltd Compounds
WO2015113451A1 (en) 2014-01-29 2015-08-06 Glaxosmithkline Intellectual Property Development Limited Compounds
WO2015148867A1 (en) * 2014-03-28 2015-10-01 Calitor Sciences, Llc Substituted heteroaryl compounds and methods of use
AU2015201630A1 (en) * 2014-03-31 2015-10-15 Commonwealth Scientific And Industrial Research Organisation Diamine compounds for phosphorescent diazaborole metal complexes and electroluminescent devices
GB2538476B (en) * 2014-05-08 2019-03-20 Tosoh F Tech Inc 5-(Trifluoromethyl)pyrimidine derivatives and method for producing same
US10058559B2 (en) 2014-05-15 2018-08-28 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Treatment or prevention of an intestinal disease or disorder
JP6262079B2 (ja) * 2014-06-02 2018-01-17 東ソー・ファインケム株式会社 4−(2,2,2−トリフルオロエトキシ)−5−(トリフルオロメチル)ピリミジン誘導体及びその製造方法
JP6431294B2 (ja) * 2014-06-16 2018-11-28 東ソー・ファインケム株式会社 5−(トリフルオロメチル)ピリミジン誘導体及びその製造法
JP6649540B2 (ja) 2014-10-14 2020-02-19 ノース・アンド・サウス・ブラザー・ファーマシー・インベストメント・カンパニー・リミテッド 置換されたヘテロアリール化合物および使用方法
WO2017046675A1 (en) 2015-09-14 2017-03-23 Pfizer Inc. Novel imidazo [4,5-c] quinoline and imidazo [4,5-c][1,5] naphthyridine derivatives as lrrk2 inhibitors
US11214565B2 (en) 2015-11-20 2022-01-04 Denali Therapeutics Inc. Compound, compositions, and methods
US11028080B2 (en) 2016-03-11 2021-06-08 Denali Therapeutics Inc. Substituted pyrimidines as LRKK2 inhibitors
ES2797301T3 (es) 2016-03-29 2020-12-01 Merck Patent Gmbh Derivados de piperidinil-propanona
CA3022231A1 (en) 2016-04-28 2017-11-02 Merck Patent Gmbh Piperidinyl derivatives
CN114315819A (zh) * 2016-06-16 2022-04-12 戴纳立制药公司 作为用于治疗神经退化性病症的lrrk2抑制剂的嘧啶-2-基氨基-1h-吡唑
CN106588885B (zh) * 2016-11-10 2019-03-19 浙江大学 2-取代芳环-嘧啶类衍生物及制备和应用
CN106588884B (zh) * 2016-11-10 2019-04-09 浙江大学 2-多取代芳环-嘧啶类衍生物及制备和医药用途
EP3586848B1 (en) 2017-02-24 2021-09-01 Daegu-Gyeongbuk Medical Innovation Foundation Pharmaceutical composition comprising compound capable of penetrating blood-brain barrier as effective ingredient for preventing or treating brain cancer
GB201705263D0 (en) * 2017-03-31 2017-05-17 Probiodrug Ag Novel inhibitors
US20200157081A1 (en) * 2017-05-24 2020-05-21 Denali Therapeutics Inc. Compounds, compositions and methods
CA3063102A1 (en) * 2017-06-30 2019-01-03 Amgen Inc. Synthesis of omecamtiv mecarbil
JP2020526543A (ja) * 2017-07-14 2020-08-31 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited ロイシンリッチリピートキナーゼ2の阻害剤
JP7254076B2 (ja) 2017-11-19 2023-04-07 サンシャイン・レイク・ファーマ・カンパニー・リミテッド 置換ヘテロアリール化合物及び使用方法
MX2020005332A (es) * 2017-11-21 2021-01-08 Denali Therapeutics Inc Polimorfos y formas solidas de un compuesto de pirimidinilamino-pirazol y metodos de produccion.
MA51339A (fr) 2017-12-20 2020-10-28 Denali Therapeutics Inc Procédé de préparation de composés pyrimidinyl-4-aminopyrazole
WO2019160037A1 (ja) * 2018-02-14 2019-08-22 国立大学法人 東京大学 酸ハロゲン化物による化合物の製造方法
US11034669B2 (en) 2018-11-30 2021-06-15 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
AR118641A1 (es) * 2019-04-11 2021-10-20 Denali Therapeutics Inc Compuestos, composiciones y métodos
EA202193285A1 (ru) * 2019-05-31 2022-03-04 Денали Терапьютикс Инк. Состав с модифицированным высвобождением соединения пиримидиниламинопиразола и способы лечения
CN110627810B (zh) * 2019-06-05 2024-05-10 中国医学科学院药用植物研究所 一种三氟甲基吡唑衍生物的制备方法
CA3170252A1 (en) * 2020-03-06 2021-09-10 Chun-Ping Chang Pyrimidine compounds and their pharmaceutical uses
JP2023524935A (ja) 2020-03-23 2023-06-14 ファニン ファーマシューティカル カンパニー リミテッド 新規なピリミジン誘導体及びこれを含む神経退行性疾患及び癌の予防又は治療用組成物
KR102342803B1 (ko) 2020-03-23 2021-12-24 환인제약 주식회사 신규한 피리미딘 유도체 및 이를 포함하는 신경퇴행성 질환 및 암의 예방 또는 치료용 조성물
WO2022084210A1 (en) 2020-10-20 2022-04-28 F. Hoffmann-La Roche Ag Combination therapy of pd-1 axis binding antagonists and lrrk2 inhitibors
TW202237119A (zh) 2020-12-10 2022-10-01 美商住友製藥腫瘤公司 Alk﹘5抑制劑和彼之用途
WO2022197577A1 (en) * 2021-03-17 2022-09-22 Merck Sharp & Dohme Llc Heteroaroyl amides as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof
JP2024511466A (ja) * 2021-03-26 2024-03-13 スミトモ ファーマ オンコロジー, インコーポレイテッド Alk-5阻害剤及びその使用
WO2023076404A1 (en) 2021-10-27 2023-05-04 Aria Pharmaceuticals, Inc. Methods for treating systemic lupus erythematosus
WO2023174946A1 (en) 2022-03-15 2023-09-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Early and non-invasive method for assessing a subject's risk of having parkinson's disease
WO2023224894A1 (en) * 2022-05-20 2023-11-23 Merck Sharp & Dohme Llc Macrocycles as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof
WO2024097394A1 (en) 2022-11-03 2024-05-10 Denali Therapeutics Inc. Solid and co-crystal forms of a pyrimidine triazole compound
WO2024112746A1 (en) 2022-11-22 2024-05-30 Denali Therapeutics Inc. Processes and intermediates for the preparation of a pyrimidine aminopyrazole compound
CN115819405A (zh) * 2022-12-20 2023-03-21 沪渝人工智能研究院 嘧啶氨基吡唑衍生物及其作为富亮氨酸重复激酶2抑制剂的应用

Family Cites Families (132)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ101496A3 (en) 1993-10-12 1996-11-13 Du Pont Merck Pharma N-alkyl-n-aryl-pyrimidinamines and derivatives thereof
CN1142817A (zh) 1993-10-12 1997-02-12 杜邦麦克制药有限公司 1n-烷基-n-芳基嘧啶胺及其衍生物
KR100643419B1 (ko) 1998-03-27 2006-11-10 얀센 파마슈티카 엔.브이. Hiv를 억제하는 피리미딘 유도체
US6458823B1 (en) 1998-06-08 2002-10-01 Wyeth Diaminopyrazoles
US6172222B1 (en) 1998-06-08 2001-01-09 American Home Products Corporation Diaminopyrazoles
CZ301367B6 (cs) 1998-11-10 2010-02-03 Janssen Pharmaceutica N. V. Derivát pyrimidinu, zpusob a meziprodukty pro jeho prípravu a lécivo pro lécení HIV na jeho bázi
CZ2002534A3 (cs) 1999-08-13 2002-07-17 Vertex Pharmaceuticals Incorporated Inhibitory protein-kináz, farmaceutické prostředky, které je obsahují, a jejich pouľití
AU775360B2 (en) 1999-09-24 2004-07-29 Janssen Pharmaceutica N.V. Antiviral compositions
US6906067B2 (en) 1999-12-28 2005-06-14 Bristol-Myers Squibb Company N-heterocyclic inhibitors of TNF-α expression
JP5230050B2 (ja) 2000-05-08 2013-07-10 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Hiv複製阻害剤
GB0016877D0 (en) 2000-07-11 2000-08-30 Astrazeneca Ab Chemical compounds
GB0021726D0 (en) 2000-09-05 2000-10-18 Astrazeneca Ab Chemical compounds
US7473691B2 (en) 2000-09-15 2009-01-06 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
HUP0302173A2 (hu) 2000-09-15 2003-09-29 Vertex Pharmaceuticals Incorporated Protein kináz inhibitorokként alkalmazható pirazolvegyületek
US6613776B2 (en) 2000-09-15 2003-09-02 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US20020111353A1 (en) 2000-12-05 2002-08-15 Mark Ledeboer Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases
US7122544B2 (en) 2000-12-06 2006-10-17 Signal Pharmaceuticals, Llc Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto
ES2265452T3 (es) 2000-12-21 2007-02-16 Vertex Pharmaceuticals Incorporated Compuestos de pirazol utiles como inhibidores de la proteina quinasa.
NZ526542A (en) 2000-12-21 2005-01-28 Glaxo Group Ltd Pyrimidineamines as angiogenesis modulators
CA2446864C (en) 2001-05-16 2011-02-15 Vertex Pharmaceuticals Incorporated Inhibitors of src and other protein kinases
WO2002096888A1 (de) 2001-05-29 2002-12-05 Schering Aktiengesellschaft Cdk inhibitorische pyrimidine, deren herstellung und verwendung als arzneimittel
GB0113041D0 (en) 2001-05-30 2001-07-18 Astrazeneca Ab Chemical compounds
JP2005500294A (ja) 2001-06-19 2005-01-06 ブリストル−マイヤーズ スクイブ カンパニー ホスホジエステラーゼ7に対するピリミジン阻害剤
EP1408978A4 (en) 2001-06-21 2005-07-13 Ariad Pharma Inc NOVEL PHENYLAMINO-PYRIMIDINES AND THEIR USE
US20030139435A1 (en) 2001-06-26 2003-07-24 Gulzar Ahmed N-heterocyclic inhibitors of TNF-alpha expression
WO2003030909A1 (en) 2001-09-25 2003-04-17 Bayer Pharmaceuticals Corporation 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer
WO2003040141A1 (en) 2001-09-28 2003-05-15 Bayer Pharmaceuticals Corporation Oxazolyl-phenyl-2,4-diamino-pyrimidine compounds and methods for treating hyperproliferative disorders
JP4460292B2 (ja) 2001-10-17 2010-05-12 ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト ピリミジン誘導体、これらの化合物を含む医薬組成物、その使用及びその調製方法
EP1453516A2 (de) 2001-10-17 2004-09-08 Boehringer Ingelheim Pharma GmbH & Co.KG 5-substituierte 4-amino-2-phenylamino-pyrimdinderivate und ihre verwendung als beta-amyloid modulatoren
AU2002367172A1 (en) 2001-12-21 2003-07-15 Bayer Pharmaceuticals Corporation 2,4-diamino-pyrimidine derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
GB0205688D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
US7288547B2 (en) 2002-03-11 2007-10-30 Schering Ag CDK-inhibitory 2-heteroaryl-pyrimidines, their production and use as pharmaceutical agents
AU2003212282A1 (en) * 2002-03-11 2003-09-22 Schering Aktiengesellschaft Cdk inhibiting 2-heteroaryl pyrimidine, the production thereof, and use thereof as a medicament
AR039540A1 (es) 2002-05-13 2005-02-23 Tibotec Pharm Ltd Compuestos microbicidas con contenido de pirimidina o triazina
GB0211019D0 (en) 2002-05-14 2002-06-26 Syngenta Ltd Novel compounds
GB0215844D0 (en) 2002-07-09 2002-08-14 Novartis Ag Organic compounds
CA2502970A1 (en) 2002-11-28 2004-06-10 Schering Aktiengesellschaft Chk-, pdk- and akt-inhibitory pyrimidines, their production and use as pharmaceutical agents
DE602004022633D1 (de) 2003-01-30 2009-10-01 Boehringer Ingelheim Pharma 2,4-diaminopyrimidinderivate, die sich als inhibitoren von pkc-theta eignen
JP4648324B2 (ja) 2003-05-21 2011-03-09 バイエル・クロツプサイエンス・アクチエンゲゼルシヤフト ヨードピラゾリルカルボキシアニリド類
WO2005009977A1 (en) 2003-07-15 2005-02-03 Neurogen Corporation Substituted pyrimidin-4-ylamina analogues as vanilloid receptor ligands
BRPI0412351A (pt) 2003-07-30 2006-09-05 Cyclacel Ltd derivados e piridilamino-pirimidina como inibidores de proteìna quinase
RS53109B (en) * 2003-07-30 2014-06-30 Rigel Pharmaceuticals Inc. 2,4 PIRIMIDINDIAMINE COMPOUNDS FOR USE IN TREATMENT OR PREVENTION OF AUTOIMMUNE DISEASES
DK1663242T3 (da) 2003-08-07 2011-08-01 Rigel Pharmaceuticals Inc 2,4-Pyrimidindiamin-forbindelser og anvendelse som antiproliferative midler
DE10349423A1 (de) 2003-10-16 2005-06-16 Schering Ag Sulfoximinsubstituierte Parimidine als CDK- und/oder VEGF-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
GB0402653D0 (en) 2004-02-06 2004-03-10 Cyclacel Ltd Compounds
JP2007537238A (ja) 2004-05-14 2007-12-20 ファイザー・プロダクツ・インク 異常細胞増殖の治療のためのピリミジン誘導体
CA2566531A1 (en) 2004-05-18 2005-12-15 Rigel Pharmaceuticals, Inc. Cycloalkyl substituted pyrimidinediamine compounds and their uses
EP1598343A1 (de) 2004-05-19 2005-11-23 Boehringer Ingelheim International GmbH 2-Arylaminopyrimidine als PLK Inhibitoren
EP1765791A1 (en) 2004-07-08 2007-03-28 Boehringer Ingelheim Pharmaceuticals Inc. Pyrimidine derivatives useful as inhibitors of pkc-theta
US7521457B2 (en) 2004-08-20 2009-04-21 Boehringer Ingelheim International Gmbh Pyrimidines as PLK inhibitors
CA2578349A1 (en) 2004-09-01 2006-03-16 Rigel Pharmaceuticals, Inc. Synthesis of 2,4-pyrimidinediamine compounds
TW200628463A (en) 2004-11-10 2006-08-16 Synta Pharmaceuticals Corp Heteroaryl compounds
ATE540035T1 (de) 2004-11-24 2012-01-15 Rigel Pharmaceuticals Inc Spiro-2,4-pyrimidindiamin-verbindungen und ihre verwendungen
NZ555474A (en) 2004-12-17 2010-10-29 Astrazeneca Ab 4-(4-(imidazol-4-yl) pyrimidin-2-ylamino) benzamides as CDK inhibitors
ATE519759T1 (de) 2004-12-30 2011-08-15 Exelixis Inc Pyrimidinderivate als kinasemodulatoren und anwendungsverfahren
DE102005008310A1 (de) 2005-02-17 2006-08-24 Schering Ag Verwendung von CDKII Inhibitoren zur Fertilitätskontrolle
EP1705177A1 (en) 2005-03-23 2006-09-27 Schering Aktiengesellschaft N-aryl-sulfoximine-substituted pyrimidines as CDK- and/or VEGF inhibitors, their production and use as pharmaceutical agents
CN101218229A (zh) 2005-05-05 2008-07-09 阿斯利康(瑞典)有限公司 吡唑基-氨基取代的嘧啶及其在癌症治疗中的应用
NZ563454A (en) 2005-06-08 2011-03-31 Rigel Pharmaceuticals Inc 2,4-diaminopyrimidine derivatives for inhibition of the JAK pathway
EP1896134A2 (en) 2005-06-13 2008-03-12 Rigel Pharmaceuticals, Inc. Methods and compositions for treating degenerative bone disorders
CA2612227C (en) 2005-06-14 2014-04-22 Taigen Biotechnology Co., Ltd. Pyrimidine compounds
US20070032514A1 (en) 2005-07-01 2007-02-08 Zahn Stephan K 2,4-diamino-pyrimidines as aurora inhibitors
WO2007023382A2 (en) 2005-08-25 2007-03-01 Pfizer Inc. Pyrimidine amino pyrazole compounds, potent kinase inhibitors
EP2266561A3 (en) 2005-09-07 2011-05-18 Merck Serono S.A. IKK Inhibitors for the Treatment of Endometriosis
WO2007035309A1 (en) * 2005-09-15 2007-03-29 Merck & Co., Inc. Tyrosine kinase inhibitors
DE102005048072A1 (de) 2005-09-24 2007-04-05 Bayer Cropscience Ag Thiazole als Fungizide
WO2007129195A2 (en) 2006-05-04 2007-11-15 Pfizer Products Inc. 4-pyrimidine-5-amino-pyrazole compounds
US8623887B2 (en) 2006-05-15 2014-01-07 Boehringer Ingelheim International Gmbh Compounds
DE102006027156A1 (de) 2006-06-08 2007-12-13 Bayer Schering Pharma Ag Sulfimide als Proteinkinaseinhibitoren
AU2007257701A1 (en) 2006-06-15 2007-12-21 Boehringer Ingelheim International Gmbh 2-anilino-4-aminoalkyleneaminopyrimidines
WO2007149789A2 (en) 2006-06-22 2007-12-27 Applera Corporation Conversion of target specific amplification to universal sequencing
WO2008016675A1 (en) 2006-08-01 2008-02-07 Praecis Pharmaceuticals Incorporated P38 kinase inhibitors
DE102006041382A1 (de) 2006-08-29 2008-03-20 Bayer Schering Pharma Ag Carbamoyl-Sulfoximide als Proteinkinaseinhibitoren
US20080194575A1 (en) 2006-10-04 2008-08-14 Naiara Beraza Treatment for non-alcoholic-steatohepatitis
MX2009005649A (es) 2006-11-27 2009-06-08 Ares Trading Sa Tratamiento para mieloma multiple.
AU2007333394C1 (en) 2006-12-08 2011-08-18 Novartis Ag Compounds and compositions as protein kinase inhibitors
GB0625196D0 (en) 2006-12-18 2007-01-24 7Tm Pharma As Modulators of cannabinoid receptor
US20100144732A1 (en) 2006-12-19 2010-06-10 Krueger Elaine B Pyrimidine kinase inhibitors
EP1939185A1 (de) 2006-12-20 2008-07-02 Bayer Schering Pharma Aktiengesellschaft Neuartige Hetaryl-Phenylendiamin-Pyrimidine als Proteinkinaseinhibitoren zur Behandlung von Krebs
US20100144706A1 (en) 2006-12-22 2010-06-10 Boehringer Ingelheim International Gmbh Compounds
WO2008099210A2 (en) 2007-02-12 2008-08-21 Merck & Co., Inc. Piperazine derivatives for treatment of ad and related conditions
DE102007010801A1 (de) 2007-03-02 2008-09-04 Bayer Cropscience Ag Diaminopyrimidine als Fungizide
TW200846344A (en) 2007-04-25 2008-12-01 Astrazeneca Ab Chemical compounds
CA2685588A1 (en) 2007-06-08 2008-12-11 Bayer Cropscience Sa Fungicide heterocyclyl-pyrimidinyl-amino derivatives
WO2009012421A1 (en) 2007-07-17 2009-01-22 Rigel Pharmaceuticals, Inc. Cyclic amine substituted pyrimidinediamines as pkc inhibitors
ES2585110T3 (es) 2007-09-28 2016-10-03 Cyclacel Limited Derivados de pirimidina como inhibidores de proteína cinasa
EP2197853B1 (en) 2007-10-09 2011-11-09 Dow AgroSciences LLC Insecticidal pyrimidinyl aryl hydrazones
MX2010005300A (es) 2007-11-16 2010-06-25 Incyte Corp 4-pirazolil-n-arilpirimidin-2-aminas y 4-pirazolil-n-heteroarilpir imidin-2-aminas como inhibidores de cinasas janus.
WO2009071535A1 (en) 2007-12-03 2009-06-11 Boehringer Ingelheim International Gmbh Diaminopyridines for the treatment of diseases which are characterised by excessive or anomal cell proliferation
JP2011506303A (ja) 2007-12-07 2011-03-03 ノバルティス アーゲー ピラゾール誘導体およびサイクリン依存性キナーゼの阻害剤としてのその使用
MX2010008926A (es) 2008-02-15 2011-02-23 Rigel Pharmaceuticals Inc Compuestos de pirimidin-2-amina y su uso como inhibidores de jak cinasas.
CL2009000600A1 (es) 2008-03-20 2010-05-07 Bayer Cropscience Ag Uso de compuestos de diaminopirimidina como agentes fitosanitarios; compuestos de diaminopirimidina; su procedimiento de preparacion; agente que los contiene; procedimiento para la preparacion de dicho agente; y procedimiento para combatir plagas de animales y/u hongos dañinos patogenos de plantas.
US20100056524A1 (en) 2008-04-02 2010-03-04 Mciver Edward Giles Compound
WO2009127642A2 (en) * 2008-04-15 2009-10-22 Cellzome Limited Use of lrrk2 inhibitors for neurodegenerative diseases
SI2300013T1 (en) 2008-05-21 2018-03-30 Adriad Pharmacaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
UY31929A (es) 2008-06-25 2010-01-05 Irm Llc Compuestos y composiciones como inhibidores de cinasa
US8445505B2 (en) 2008-06-25 2013-05-21 Irm Llc Pyrimidine derivatives as kinase inhibitors
US8716486B2 (en) 2008-06-25 2014-05-06 Edison Pharmaceuticals, Inc. 2-heterocyclylaminoalkyl-(p-quinone) derivatives for treatment of oxidative stress diseases
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
RU2473549C2 (ru) 2008-07-31 2013-01-27 Дженентек, Инк. Пиримидиновые соединения, композиции и способы применения
EP2325175A4 (en) 2008-09-01 2012-03-21 Astellas Pharma Inc 2,4-DIAMINOPYRIMIDINVERBINDUNG
US20110230478A1 (en) 2008-09-03 2011-09-22 Bayer ScienceCrop AG 4-Alkyl-substituted diaminopyrimidines
JP2012501978A (ja) 2008-09-03 2012-01-26 バイエル・クロップサイエンス・アーゲー 殺菌剤としてのヘテロ環置換アニリノピリミジン類
EA201100434A1 (ru) 2008-09-03 2011-10-31 Байер Кропсайенс Аг Гетероциклически замещенные анилинопиримидины в качестве фунгицидов
EP2161259A1 (de) 2008-09-03 2010-03-10 Bayer CropScience AG 4-Halogenalkylsubstituierte Diaminopyrimidine als Fungizide
WO2010028179A1 (en) 2008-09-03 2010-03-11 Dr. Reddy's Laboratories Ltd. Heterocyclic compounds as gata modulators
TW201016676A (en) 2008-10-03 2010-05-01 Astrazeneca Ab Heterocyclic derivatives and methods of use thereof
UY32240A (es) 2008-11-14 2010-06-30 Boeringer Ingelheim Kg Nuevas 2,4-diaminopirimidinas, sus sales farmacéuticamente aceptables, composiciones conteniéndolas y aplicaciones.
GB0821307D0 (en) 2008-11-21 2008-12-31 Summit Corp Plc Compounds for treatment of duchenne muscular dystrophy
JP5908728B2 (ja) 2009-01-06 2016-04-26 ダナ ファーバー キャンサー インスティテュート インコーポレイテッド ピリミド−ジアゼピノンキナーゼ骨格化合物及び疾患を治療する方法
US20110071158A1 (en) 2009-03-18 2011-03-24 Boehringer Ingelheim International Gmbh New compounds
AU2010231694A1 (en) * 2009-03-30 2011-10-06 Astellas Pharma Inc. Pyrimidine compound
CA2758614A1 (en) 2009-04-14 2010-10-21 Cellzome Limited Fluoro substituted pyrimidine compounds as jak3 inhibitors
WO2010129053A2 (en) 2009-05-05 2010-11-11 Dana Farber Cancer Institute Egfr inhibitors and methods of treating disorders
TW201100441A (en) 2009-06-01 2011-01-01 Osi Pharm Inc Amino pyrimidine anticancer compounds
MX2011013325A (es) 2009-06-10 2012-04-30 Abbott Lab 2-(lh-pirazol-4-ilamino)-pirimidina como inhibidores de cinasa.
CA2763717A1 (en) 2009-06-10 2010-12-16 Cellzome Limited Pyrimidine derivatives as zap-70 inhibitors
TW201103904A (en) 2009-06-11 2011-02-01 Hoffmann La Roche Janus kinase inhibitor compounds and methods
US20120172384A1 (en) 2009-06-18 2012-07-05 Mihiro Sunose Heterocyclylaminopyrimidines as kinase inhibitors
CA2763720A1 (en) 2009-06-18 2010-12-23 Cellzome Limited Sulfonamides and sulfamides as zap-70 inhibitors
RU2012114902A (ru) 2009-09-16 2013-10-27 Авила Терапьютикс, Инк. Конъюгаты и ингибиторы протеинкиназы
EP2483254B1 (en) 2009-09-29 2014-08-13 Glaxo Group Limited Novel compounds
MY160820A (en) 2009-11-13 2017-03-31 Genosco Kinase inhibitors
ME02505B (me) 2009-12-29 2017-02-20 Aptevo Res & Development Llc Heterodimerni vezujući proteini i njihove upotrebe
US8470820B2 (en) 2010-01-22 2013-06-25 Hoffman-La Roche Inc. Nitrogen-containing heteroaryl derivatives
CN103038230B (zh) * 2010-06-04 2016-05-25 霍夫曼-拉罗奇有限公司 作为lrrk2调节剂的氨基嘧啶衍生物
BR112014011219B1 (pt) * 2011-11-29 2022-08-23 Genentech, Inc. Derivados de aminopirimidina, seus usos, e composição farmacêutica
PT2785711T (pt) * 2011-11-29 2016-09-30 Hoffmann La Roche Derivados de 2-(fenil ou pirid-3- il)aminopiridinacomo moduladores de lrrk2 quinase, para o tratamento da doença de parkinson
AR089182A1 (es) * 2011-11-29 2014-08-06 Hoffmann La Roche Derivados de aminopirimidina como moduladores de lrrk2
BR112014011850B1 (pt) * 2011-11-29 2022-01-11 Genentech, Inc Derivados de aminopirimidina, seus usos, e composição farmacêutica
KR101996699B1 (ko) * 2011-11-30 2019-07-04 제넨테크, 인크. Lrrk2에 대해 양전자 방사 단층촬영(pet) 이미징을 위한 불소-18 및 탄소-11 표지된 방사선 리간드

Also Published As

Publication number Publication date
HK1187605A1 (en) 2014-04-11
MA34644B1 (fr) 2013-11-02
TW201302733A (zh) 2013-01-16
JP5986094B2 (ja) 2016-09-06
RS59106B1 (sr) 2019-09-30
BR112013011600B1 (pt) 2022-01-11
JP2017008074A (ja) 2017-01-12
JP6298115B2 (ja) 2018-03-20
JP6524284B2 (ja) 2019-06-05
ECSP13012611A (es) 2013-07-31
HRP20172006T1 (hr) 2018-02-09
SI3124483T1 (sl) 2019-10-30
BR112013011600A8 (pt) 2021-09-08
AU2011328139A1 (en) 2013-04-04
LT2638031T (lt) 2017-12-11
SG189043A1 (en) 2013-05-31
CY1120073T1 (el) 2018-12-12
EP3590933A1 (en) 2020-01-08
CA3017869C (en) 2021-07-27
NO2638031T3 (hu) 2018-03-10
KR101566091B1 (ko) 2015-11-04
DK3124483T3 (da) 2019-09-02
PL3124483T3 (pl) 2020-03-31
EP2638031B9 (en) 2020-01-08
CN103313978B (zh) 2015-04-15
EP3124483A1 (en) 2017-02-01
RS56583B1 (sr) 2018-02-28
MX2013005199A (es) 2013-06-28
KR20130093657A (ko) 2013-08-22
SI2638031T1 (en) 2018-02-28
CA2812669C (en) 2018-11-06
JP2018109038A (ja) 2018-07-12
JP2013545741A (ja) 2013-12-26
EP3124483B1 (en) 2019-07-10
ES2746134T3 (es) 2020-03-04
EP3590933B1 (en) 2021-01-06
CN103313978A (zh) 2013-09-18
US8815882B2 (en) 2014-08-26
CA3017869A1 (en) 2012-05-18
HUE037844T2 (hu) 2018-09-28
PT3124483T (pt) 2019-10-02
HRP20191781T1 (hr) 2019-12-27
EP2638031B1 (en) 2017-10-11
BR112013011600A2 (pt) 2016-08-09
AR083813A1 (es) 2013-03-27
PT2638031T (pt) 2018-01-03
LT3124483T (lt) 2019-09-25
CA2812669A1 (en) 2012-05-18
DK2638031T3 (en) 2017-12-11
WO2012062783A1 (en) 2012-05-18
PL2638031T3 (pl) 2018-03-30
ES2653967T3 (es) 2018-02-09
EP2638031A1 (en) 2013-09-18
US20120157427A1 (en) 2012-06-21
IL225234A0 (en) 2013-06-27

Similar Documents

Publication Publication Date Title
HRP20160771T1 (hr) Derivati aminopirimidina kao modulatori za lrrk2
HK1187605A1 (en) Pyrazole aminopyrimidine derivatives as lrrk2 modulators lrrk2
HK1200820A1 (zh) 作為 調節劑的吡唑氨基嘧啶衍生物
HK1210778A1 (en) Pyrimidine pyrazolyl derivatives
AP2948A (en) Thienopyrmidinedione derivatives as TRPA1 modulators
HK1166081A1 (en) Isothiazolo-pyrimidinedione derivatives as trpa1 modulators
HK1200819A1 (en) Pyrazole aminopyrimidine derivatives as lrrk2 modulators for use in the treatment of parkinsons disease lrrk2
ZA201304282B (en) Pyrazole derivative
ZA201209029B (en) Novel pyrimidine derivatives
HK1191862A1 (zh) 吡唑衍生物
HK1201836A1 (en) Novel pyrrole derivatives
EP2542075A4 (en) Fluorouracil DERIVATIVES
GB201106796D0 (en) Pyrrole derivatives